282 related articles for article (PubMed ID: 33338644)
1. Anticoagulant selection in relation to the SAMe-TT
Ntaios G; Huisman MV; Diener HC; Halperin JL; Teutsch C; Marler S; Gurusamy VK; Thompson M; Lip GYH; Olshansky B;
Hellenic J Cardiol; 2021; 62(2):152-157. PubMed ID: 33338644
[TBL] [Abstract][Full Text] [Related]
2. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.
Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Bartels DB; Lip GY;
J Am Coll Cardiol; 2017 Feb; 69(7):777-785. PubMed ID: 28209218
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
[TBL] [Abstract][Full Text] [Related]
4. Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry.
Huisman MV; Teutsch C; Lu S; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Lohmann R; Gurusamy VK; Bartels DB; Lip GYH;
Clin Res Cardiol; 2022 May; 111(5):548-559. PubMed ID: 35294623
[TBL] [Abstract][Full Text] [Related]
5. The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective 'Real-world' Inception Cohort Study.
Roldán V; Cancio S; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
Am J Med; 2015 Nov; 128(11):1237-43. PubMed ID: 26087049
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme.
Mazurek M; Halperin JL; Huisman MV; Diener HC; Dubner SJ; Ma CS; Rothman KJ; Healey JS; Teutsch C; Paquette M; França LR; Lu S; Bartels DB; Lip GYH
Europace; 2020 Jan; 22(1):47-57. PubMed ID: 31651951
[TBL] [Abstract][Full Text] [Related]
7. Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA-AF Phase III Registry.
Bayer V; Kotalczyk A; Kea B; Teutsch C; Larsen P; Button D; Huisman MV; Lip GYH; Olshansky B
J Am Heart Assoc; 2022 Mar; 11(6):e023907. PubMed ID: 35243870
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II.
Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma C; Zint K; Elsaesser A; Bartels DB; Lip GY;
Am J Med; 2015 Dec; 128(12):1306-13.e1. PubMed ID: 26239094
[TBL] [Abstract][Full Text] [Related]
9. A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin.
Poli D; Antonucci E; Testa S; Lip GY
Intern Emerg Med; 2014 Jun; 9(4):443-7. PubMed ID: 24652166
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the mean time in the therapeutic INR range and the SAME-TT2R2 score in patients with atrial fibrillation and cognitive impairment.
Gorzelak-Pabiś P; Zyzak S; Krewko Ł; Broncel M
Pol Arch Med Wewn; 2016 Aug; 126(7-8):494-501. PubMed ID: 27511466
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of the SAME-TT2R2 score to predict anticoagulation control on VKA in patients with atrial fibrillation and obstructive sleep apnea.
Szymanski FM; Lip GY; Filipiak KJ; Platek AE; Karpinski G
Int J Cardiol; 2016 Feb; 204():200-5. PubMed ID: 26670173
[TBL] [Abstract][Full Text] [Related]
12. Relation of the SAMe-TT2R2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: Observations from the SPORTIF trials.
Proietti M; Lane DA; Lip GY
Int J Cardiol; 2016 Aug; 216():168-72. PubMed ID: 27156060
[TBL] [Abstract][Full Text] [Related]
13. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
[TBL] [Abstract][Full Text] [Related]
14. Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry.
Esteve-Pastor MA; Rivera-Caravaca JM; Roldán-Rabadán I; Roldán V; Muñiz J; Raña-Míguez P; Ruiz-Ortiz M; Cequier Á; Bertomeu-Martínez V; Badimón L; Anguita M; Lip GYH; Marín F;
Europace; 2018 Sep; 20(9):1435-1441. PubMed ID: 29095971
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
16. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.
Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S
BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389
[TBL] [Abstract][Full Text] [Related]
17. Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program.
Beier L; Lu S; França LR; Marler S; Lip GYH; Huisman MV; Teutsch C; Halperin JL; Zint K; Diener HC; Baker L; Ma CS; Paquette M; Bartels DB; Dubner SJ; Lyrer P; Senges J; Rothman KJ
PLoS One; 2022; 17(10):e0274237. PubMed ID: 36201473
[TBL] [Abstract][Full Text] [Related]
18. Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
Konieczyńska M; Sobieraj E; Bryk AH; Dębski M; Polak M; Podolec P; Małecka B; Pająk A; Desteghe L; Heidbuchel H; Undas A
Kardiol Pol; 2018; 76(7):1089-1096. PubMed ID: 29528483
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety outcomes of patients with atrial fibrillation compared between warfarin and non-vitamin K antagonist oral anticoagulants based on SAMe-TT
Methavigul K; Yindeengam A; Krittayaphong R
BMC Cardiovasc Disord; 2023 Jan; 23(1):43. PubMed ID: 36690928
[TBL] [Abstract][Full Text] [Related]
20. Incidence and Risk Factors for Residual Adverse Events Despite Anticoagulation in Atrial Fibrillation: Results From Phase II/III of the GLORIA-AF Registry.
Ding WY; Lane DA; Gupta D; Huisman MV; Lip GYH;
J Am Heart Assoc; 2022 Aug; 11(15):e026410. PubMed ID: 35876418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
